On Nov. 13, 2013, Genentech announced that it’s drug Gazyva (obinutuzumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of people with previously untreated CLL.

Gazyva is a monoclonal antibody designed to attach CD20, a protein found only on B-cells. It attacks targeted cells both directly and together with the body’s immune system.